VISTIN PHARMA ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.9 NOK | +1.70% |
|
0.00% | +2.58% |
| 24/04 | Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 24/04 | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 |
| Sales 2021 | 279M 25.27M 2.11B | Sales 2022 | 305M 27.65M 2.31B | Capitalization | 701M 63.55M 5.3B |
|---|---|---|---|---|---|
| Net income 2021 | 24M 2.18M 182M | Net income 2022 | -4M -363K -30.25M | EV / Sales 2021 | 2.96 x |
| Net cash position 2021 | 34.36M 3.12M 260M | Net Debt 2022 | 47.73M 4.33M 361M | EV / Sales 2022 | 2.45 x |
| P/E ratio 2021 |
34.6
x | P/E ratio 2022 |
-144
x | Employees | 78 |
| Yield 2021 |
3.87% | Yield 2022 |
4.75% | Free-Float | 45.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vistin Pharma ASA
| 1 day | +1.70% | ||
| Current month | +7.17% | ||
| 1 month | +4.37% | ||
| 3 months | +3.91% | ||
| 6 months | +4.82% | ||
| Current year | +2.58% |
1 week
23.00
24.30
1 month
21.9024.30
Current year
21.6024.50
1 year
20.6025.10
3 years
11.2526.00
5 years
5.0029.45
10 years
5.0029.45
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/20/01 | |
| Director of Finance/CFO | - | 02/20/02 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 01/20/01 | |
| Director/Board Member | 62 | 06/15/06 | |
| Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 23.9 | +1.70% | 1,465 |
| 25/24/25 | 23.5 | 0.00% | 9,730 |
| 24/24/24 | 23.5 | -3.29% | 39,831 |
| 23/24/23 | 24.3 | +0.41% | 16,505 |
| 22/24/22 | 24.2 | +1.26% | 6,225 |
Real-time Oslo Bors, April 26, 2024 at 08:15 pm IST
More quotes
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâs customers are pharmaceutical companies worldwide.
Sector
Pharmaceuticals
Calendar
23/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +2.58% | 95.97M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- VISTN Stock
